These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 33831375)

  • 1. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes.
    Dentro SC; Leshchiner I; Haase K; Tarabichi M; Wintersinger J; Deshwar AG; Yu K; Rubanova Y; Macintyre G; Demeulemeester J; Vázquez-García I; Kleinheinz K; Livitz DG; Malikic S; Donmez N; Sengupta S; Anur P; Jolly C; Cmero M; Rosebrock D; Schumacher SE; Fan Y; Fittall M; Drews RM; Yao X; Watkins TBK; Lee J; Schlesner M; Zhu H; Adams DJ; McGranahan N; Swanton C; Getz G; Boutros PC; Imielinski M; Beroukhim R; Sahinalp SC; Ji Y; Peifer M; Martincorena I; Markowetz F; Mustonen V; Yuan K; Gerstung M; Spellman PT; Wang W; Morris QD; Wedge DC; Van Loo P;
    Cell; 2021 Apr; 184(8):2239-2254.e39. PubMed ID: 33831375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
    McGranahan N; Favero F; de Bruin EC; Birkbak NJ; Szallasi Z; Swanton C
    Sci Transl Med; 2015 Apr; 7(283):283ra54. PubMed ID: 25877892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles of Reconstructing the Subclonal Architecture of Cancers.
    Dentro SC; Wedge DC; Van Loo P
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28270531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.
    Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA
    Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
    Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
    Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decomposing the subclonal structure of tumors with two-way mixture models on copy number aberrations.
    Tai AS; Peng CH; Peng SC; Hsieh WP
    PLoS One; 2018; 13(12):e0206579. PubMed ID: 30540749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
    Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
    Elife; 2020 May; 9():. PubMed ID: 32401198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the influence of mutation detection on tumour subclonal reconstruction.
    Liu LY; Bhandari V; Salcedo A; Espiritu SMG; Morris QD; Kislinger T; Boutros PC
    Nat Commun; 2020 Dec; 11(1):6247. PubMed ID: 33288765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CloneSig can jointly infer intra-tumor heterogeneity and mutational signature activity in bulk tumor sequencing data.
    Abécassis J; Reyal F; Vert JP
    Nat Commun; 2021 Sep; 12(1):5352. PubMed ID: 34504064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CloneCNA: detecting subclonal somatic copy number alterations in heterogeneous tumor samples from whole-exome sequencing data.
    Yu Z; Li A; Wang M
    BMC Bioinformatics; 2016 Aug; 17():310. PubMed ID: 27538789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLImAT-HET: detecting subclonal copy number alterations and loss of heterozygosity in heterogeneous tumor samples from whole-genome sequencing data.
    Yu Z; Li A; Wang M
    BMC Med Genomics; 2017 Mar; 10(1):15. PubMed ID: 28298214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phylogenetic Quantification of Intratumor Heterogeneity.
    Watkins TBK; Schwarz RF
    Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 28710259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability.
    Raynaud F; Mina M; Tavernari D; Ciriello G
    PLoS Genet; 2018 Sep; 14(9):e1007669. PubMed ID: 30212491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MixClone: a mixture model for inferring tumor subclonal populations.
    Li Y; Xie X
    BMC Genomics; 2015; 16 Suppl 2(Suppl 2):S1. PubMed ID: 25707430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.
    Farmanbar A; Firouzi S; Makałowski W; Kneller R; Iwanaga M; Utsunomiya A; Nakai K; Watanabe T
    Neoplasia; 2018 Sep; 20(9):883-893. PubMed ID: 30032036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.
    Suzuki Y; Ng SB; Chua C; Leow WQ; Chng J; Liu SY; Ramnarayanan K; Gan A; Ho DL; Ten R; Su Y; Lezhava A; Lai JH; Koh D; Lim KH; Tan P; Rozen SG; Tan IB
    Mol Oncol; 2017 Feb; 11(2):124-139. PubMed ID: 28145097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational implications of tumor heterogeneity.
    Jamal-Hanjani M; Quezada SA; Larkin J; Swanton C
    Clin Cancer Res; 2015 Mar; 21(6):1258-66. PubMed ID: 25770293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of lung cancer and impact of subclonal selection in TRACERx.
    Frankell AM; Dietzen M; Al Bakir M; Lim EL; Karasaki T; Ward S; Veeriah S; Colliver E; Huebner A; Bunkum A; Hill MS; Grigoriadis K; Moore DA; Black JRM; Liu WK; Thol K; Pich O; Watkins TBK; Naceur-Lombardelli C; Cook DE; Salgado R; Wilson GA; Bailey C; Angelova M; Bentham R; Martínez-Ruiz C; Abbosh C; Nicholson AG; Le Quesne J; Biswas D; Rosenthal R; Puttick C; Hessey S; Lee C; Prymas P; Toncheva A; Smith J; Xing W; Nicod J; Price G; Kerr KM; Naidu B; Middleton G; Blyth KG; Fennell DA; Forster MD; Lee SM; Falzon M; Hewish M; Shackcloth MJ; Lim E; Benafif S; Russell P; Boleti E; Krebs MG; Lester JF; Papadatos-Pastos D; Ahmad T; Thakrar RM; Lawrence D; Navani N; Janes SM; Dive C; Blackhall FH; Summers Y; Cave J; Marafioti T; Herrero J; Quezada SA; Peggs KS; Schwarz RF; Van Loo P; Miedema DM; Birkbak NJ; Hiley CT; Hackshaw A; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):525-533. PubMed ID: 37046096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 20. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
    Savas P; Teo ZL; Lefevre C; Flensburg C; Caramia F; Alsop K; Mansour M; Francis PA; Thorne HA; Silva MJ; Kanu N; Dietzen M; Rowan A; Kschischo M; Fox S; Bowtell DD; Dawson SJ; Speed TP; Swanton C; Loi S
    PLoS Med; 2016 Dec; 13(12):e1002204. PubMed ID: 28027312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.